Kairos Pharma (KAPA) EBIAT (2024 - 2025)
Kairos Pharma's EBIAT history spans 2 years, with the latest figure at -$1.4 million for Q2 2025.
- For Q2 2025, EBIAT fell 462.06% year-over-year to -$1.4 million; the TTM value through Jun 2025 reached -$4.7 million, changed N/A, while the annual FY2025 figure was -$5.4 million, 109.26% down from the prior year.
- EBIAT reached -$1.4 million in Q2 2025 per KAPA's latest filing, down from -$1.3 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$253000.0 in Q2 2024 to a low of -$1.4 million in Q2 2025.